BG104914A - Paroxetine maleate - Google Patents
Paroxetine maleateInfo
- Publication number
- BG104914A BG104914A BG104914A BG10491400A BG104914A BG 104914 A BG104914 A BG 104914A BG 104914 A BG104914 A BG 104914A BG 10491400 A BG10491400 A BG 10491400A BG 104914 A BG104914 A BG 104914A
- Authority
- BG
- Bulgaria
- Prior art keywords
- paroxetine maleate
- paroxetine
- maleate
- depression
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9807627.6A GB9807627D0 (en) | 1998-04-09 | 1998-04-09 | Novel compounds |
| GBGB9823856.1A GB9823856D0 (en) | 1998-10-30 | 1998-10-30 | Novel compound |
| PCT/GB1999/001106 WO1999052901A1 (en) | 1998-04-09 | 1999-04-09 | Paroxetine maleate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG104914A true BG104914A (en) | 2001-10-31 |
Family
ID=26313449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG104914A BG104914A (en) | 1998-04-09 | 2000-11-07 | Paroxetine maleate |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1073652A1 (ja) |
| JP (1) | JP2002511466A (ja) |
| KR (1) | KR20010042552A (ja) |
| CN (1) | CN1305474A (ja) |
| AP (1) | AP2000001950A0 (ja) |
| AU (1) | AU3433499A (ja) |
| BG (1) | BG104914A (ja) |
| BR (1) | BR9909529A (ja) |
| CA (1) | CA2327450A1 (ja) |
| EA (1) | EA200001050A1 (ja) |
| HU (1) | HUP0103651A3 (ja) |
| ID (1) | ID26879A (ja) |
| IL (1) | IL138920A0 (ja) |
| NO (1) | NO20005037L (ja) |
| PL (1) | PL343378A1 (ja) |
| SK (1) | SK15032000A3 (ja) |
| TR (1) | TR200002939T2 (ja) |
| WO (1) | WO1999052901A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231833B1 (en) | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
| GB9827431D0 (en) * | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel compound |
| GB9827387D0 (en) * | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel process |
| GB9914585D0 (en) * | 1999-06-22 | 1999-08-25 | Smithkline Beecham Plc | Novel process |
| NL1017421C2 (nl) | 2001-02-21 | 2002-01-15 | Synthon Bv | Werkwijze voor het vervaardigen van paroxetine. |
| KR100672184B1 (ko) | 2004-09-21 | 2007-01-19 | 주식회사종근당 | 파록세틴의 콜린산 또는 콜린산 유도체 염 |
| ITTO20060143A1 (it) * | 2006-02-28 | 2007-09-01 | Bridgestone Corp | Pneumatico |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| EP1078925A1 (en) * | 1997-06-10 | 2001-02-28 | Synthon B.V. | 4-Phenylpiperidine compounds |
-
1999
- 1999-04-09 HU HU0103651A patent/HUP0103651A3/hu unknown
- 1999-04-09 TR TR2000/02939T patent/TR200002939T2/xx unknown
- 1999-04-09 CA CA002327450A patent/CA2327450A1/en not_active Abandoned
- 1999-04-09 IL IL13892099A patent/IL138920A0/xx unknown
- 1999-04-09 EA EA200001050A patent/EA200001050A1/ru unknown
- 1999-04-09 WO PCT/GB1999/001106 patent/WO1999052901A1/en not_active Application Discontinuation
- 1999-04-09 AP APAP/P/2000/001950A patent/AP2000001950A0/en unknown
- 1999-04-09 KR KR1020007011214A patent/KR20010042552A/ko not_active Application Discontinuation
- 1999-04-09 SK SK1503-2000A patent/SK15032000A3/sk unknown
- 1999-04-09 ID IDW20002033A patent/ID26879A/id unknown
- 1999-04-09 EP EP99915911A patent/EP1073652A1/en not_active Ceased
- 1999-04-09 PL PL99343378A patent/PL343378A1/xx not_active Application Discontinuation
- 1999-04-09 JP JP2000543459A patent/JP2002511466A/ja active Pending
- 1999-04-09 CN CN99807148A patent/CN1305474A/zh active Pending
- 1999-04-09 AU AU34334/99A patent/AU3433499A/en not_active Abandoned
- 1999-04-09 BR BR9909529-7A patent/BR9909529A/pt not_active Application Discontinuation
-
2000
- 2000-10-06 NO NO20005037A patent/NO20005037L/no not_active Application Discontinuation
- 2000-11-07 BG BG104914A patent/BG104914A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2327450A1 (en) | 1999-10-21 |
| HUP0103651A3 (en) | 2002-12-28 |
| TR200002939T2 (tr) | 2001-02-21 |
| EA200001050A1 (ru) | 2001-04-23 |
| AU3433499A (en) | 1999-11-01 |
| BR9909529A (pt) | 2000-12-12 |
| JP2002511466A (ja) | 2002-04-16 |
| IL138920A0 (en) | 2001-11-25 |
| ID26879A (id) | 2001-02-15 |
| EP1073652A1 (en) | 2001-02-07 |
| NO20005037L (no) | 2000-12-05 |
| HUP0103651A2 (en) | 2002-08-28 |
| KR20010042552A (ko) | 2001-05-25 |
| SK15032000A3 (sk) | 2001-04-09 |
| CN1305474A (zh) | 2001-07-25 |
| NO20005037D0 (no) | 2000-10-06 |
| PL343378A1 (en) | 2001-08-13 |
| AP2000001950A0 (en) | 2000-12-31 |
| WO1999052901A1 (en) | 1999-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2365772A (en) | Factor | |
| MXPA02004770A (es) | Composiciones terapeuticas y metodos para su uso. | |
| PL327659A1 (en) | Disinfecting compositions and surface disinfecting methods | |
| HU9503605D0 (en) | Use of nona- and decapeptides in the preparation of a drug for the treatment of aids | |
| AU124792S (en) | Bowl | |
| HK1020259A1 (en) | Composition for use in the treatment and prevention of hyperuricemia. | |
| HUP0103845A3 (en) | Disinfecting composition and its use | |
| BG105256A (en) | Muscarinic agonists and antagonists | |
| ZA975288B (en) | The use of TCET in the prophylaxis and treatment of allergies. | |
| IL115589A0 (en) | Use of cck-b antagonists in pharmaceutical compositions | |
| AU1657097A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
| CY2482B1 (en) | Paroxetine in treatment of depression. | |
| HK1025246A1 (en) | The extract of pine needle and the use thereof. | |
| BG104914A (en) | Paroxetine maleate | |
| HUP0101528A3 (en) | The treatment of fertility disorders use of lhrh antagonists and antioestrogens in | |
| BR9708109A (pt) | Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinametanol no tratamento de distúrbios depressivos e distúrbios bipolares | |
| ZA981781B (en) | The use of levobupivacaine in treating migraine | |
| HUP0100781A3 (en) | Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia and pharmaceutical compositions containing them | |
| NZ525774A (en) | Use of SARP-1 for the treatment and/or prevention of scleroderma | |
| GB9802542D0 (en) | New use | |
| MD980129A (en) | Antiherpetic remedy | |
| AP2000001963A0 (en) | Paroxetine ascorbate. | |
| AU4506499A (en) | Novel 2,4-diaminophenol derivatives and the use thereof | |
| EP1000569A4 (en) | CHAIR AND ITS TURNTABLE | |
| EP1032266A4 (en) | USE OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION IN THE TREATMENT OF ARTHRITIS |